AlbertoJoseMonteroMDMBA, CPHQ

Oncology • Cleveland, OH

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Clinical Director Breast Cancer Program UH/Seidman Cancer Center at University Hospitals

Join to view full profile

Dr. Montero is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Montero's full profile

Already have an account?

Office
UH Cleveland Medical Center
11100 Euclid Ave Department of Medicine-Hematology and Oncology
Cleveland, OH 44106
Phone+1 216-844-3951

Fax+1 216-844-5234

Education & Training

Case Western Reserve UniversityMPOD, Organizational Development , 2024 - 2026
University of Miami School of BusinessMBA, 2011 - 2013
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1999 - 2002
University of Texas Medical Branch School of MedicineClass of 1999
University of Texas at Austin Dell Medical SchoolB.A., Summa Cum Laude, 1990 - 1994

Certifications & Licensure

FL State Medical License 2008 - 2026
OH State Medical License 2013 - 2026
TX State Medical License 2002 - 2025
SC State Medical License 2005 - 2009
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Clinical Director, Breast Cancer Medical Oncology Program University Hospitals, 2020
Six Sigma Green Belt University of Miami School of Business, 2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Six Sigma Champion University of Miami School of Business, 2012
Papanicolaou Corps for Cancer Research Pap Corps Fellow 2010
Methods in Cancer Research Workshop Travel Award ASCO/AACR, 2004
Travel Award School of Breast Oncology Course, 2004
Division of Pathology Tropical Medicine Research Award 1998
McLaughlin Medical Student Fellow 1998
Dean's List UTMB Medical School, 1995
Join now to see all

Clinical Trials

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer Start of enrollment: 2007 Jun 04
Completed
Phase 2
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer Start of enrollment: 2013 Feb 01
Completed
Phase 2
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
Immunological Responses of COVID-19 Vaccination Start of enrollment: 2021 May 21
Completed
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Adverse social determinants of health elevate uncontrolled hypertension risk: a cardio-oncology prospective cohort study.
Priyanshu Nain, Nickolas Stabellini, Omar M Makram, Johnathan Rast, Sandeep Yerraguntla
JNCI Cancer Spectrum. 2024-09-02
Allostatic Load/Chronic Stress and Cardiovascular Outcomes in Patients Diagnosed With Breast, Lung, or Colorectal Cancer.
Nickolas Stabellini, Jennifer Cullen, Marcio S Bittencourt, Justin X Moore, Arnethea Sutton
Journal of the American Heart Association. 2024-07-16
2 citations
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.
Miguel Martín, Elgene Lim, Mariana Chavez-MacGregor, Aditya Bardia, Jiong Wu
Journal of Clinical Oncology. 2024-06-20

Journal Articles

Re: Xie, J, Diener M, De G et al Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative...
Diaby V, Adunlin G, Montero AJ, J Med Econ, 2/10/2014
Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L
Diaz-Montero CM, Zidan AA, Pallin MF, Anagnostopoulos V, Salem ML, Wieder E, Komanduri K, Montero AJ , Lichtenheld MG, Immunol Res, 11/12/2013
Breast Cancer Survival Poorer in Black Women: Commentary
Montero AJ, Healio/HemOnc Today, 8/1/2013
A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer
Tan PS, Haaland B, Montero AJ , Lopes G, Breast Cancer Res Treat, 3/31/2013
Influence of Treatment Modality in Outcomes for Different Stages of Resectable Esophageal Adenocarcinomas
Allan BJ, Pedroso F, Gennis ER, Livingstone AS, Montero A , Lally B, Ardalan B, Koniaris LG, Solomon NL, Franceschi D, Ann Surg Oncol, 3/1/2013
Molecular Profiling for Breast Cancer: A Comprehensive Review
Kittaneh M, Montero AJ , Gluck S, Biomarkers in Cancer, 1/1/2013
Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review
Ochoa R, Bejarano PA, Gluck S, Montero AJ, J Med Case Rep, 11/1/2012
Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple- Negative Metastatic Breast Cancer
Montero A , Gluck S, Case Rep Oncol, 9/1/2012
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low- dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial
Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, Lee D, Sung MW, Gulec SA, Goldsmith SJ, Manzone T, Holt M, O'Neil BH, Hall N, Montero AJ , K..., Cancer, 5/8/2012
A Phase II Trial of nab- Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer
Hosein PJ, de Lima Lopes G Jr, Pastorini VH, Gomez C, Macintyre J, Zayas G, Reis I, Montero AJ , Merchan JR, Rocha Lima CM, Am J Clin Oncol, 2/2/2012
Myeloid-derived Suppressor Cells in Cancer Patients: A Clinical Perspective
Montero AJ , Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S, J Immunother, 2/1/2012
Fighting fire with fire: rekindling the bevacizumab debate
Montero AJ, Vogel C, N Engl J Med, 1/26/2012
Search for novel therapies for triple negative breast cancers (TNBC); analogs of luteinizing hormone-releasing hormone (LHRH) and growth hormone-releasing hormone (GNRH)
Buchholz S, Seitz S, Engel J, Montero A, Ortmann O, Perez R, Block NL, Schally AV, Horm Mol Biol Clin Investig, 1/1/2012
Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review
Montero AJ , Adams B, Diaz-Montero CM, Gluck S, Expert Review of Clinical Pharmacology, 5/1/2011
Bayraktar UD, Chen E, Bayraktar S, Sands LR, Marchetti F, Montero AJ , Rocha-Lima CM?
Bayraktar UD, Chen E, Bayraktar S, Sands LR, Marchetti F, Montero AJ , Rocha-Lima CM, Cancer, 12/17/2010
Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma
Yang R, Cheung MC, Byrne MM, J Xiaoling, Montero AJ , Jones C, Koniaris LG, Archives of Surgery, 1/1/2010
Cytokines and Angiogenic Factors in Metastatic Renal Cell Cancer: Association of Pretreatment Serum Levels with Survival
Montero AJ , Diaz-Montero CM, Liu, J, McIntyre BW, Logothetis C, Tannir N, Ann Oncol, 10/1/2009
Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination anti-tumor respo...
Salem ML, Diaz-Montero C, Alkhami, A, Montero AJ , Cole DJ, J Immunol, 2/15/2009
Increased Levels of Circulating Myeloid-Derived Suppressor Cells in Solid Tumor Patients Correlate With Advanced Clinical Cancer Stage, Increased Tumor Burden, and Cyc...
Marcela Diaz-Montero C, Salem ML, Garrett-Mayer E, Cole DJ, Montero AJ, Cancer Immunol Immunother, 1/1/2009
Gastrointestinal Stromal Tumors: Review of Molecular Biology and Clinical Implications
Jiang Y, Milling DL, Montero AJ, Gastrointestinal Cancer Research, 9/1/2008
Priming of naive cells in the presence of IL-12 selectively enhances the survival of CD8 +CD62L hi cells and results in superior anti-tumor activity
Diaz-Montero CM, El Naggar S, El Naggar R, Al Khami A, Montero AJ , Cole DJ, Salem ML, Cancer Immunol Immunother, 4/1/2008
Gemcitabine and taxanes in metastatic breast cancer: a systematic review
Gudena V, Montero AJ , Gluck S, Therapeutics and Clinical Risk Management, 1/1/2008
Deng WG, Montero AJ, Wu, KK, Arterioscler Thromb Vasc Biol, 8/1/2007
Fatal Rhabdomyolysis as a complication of Et-743 (Yondelis) Chemotherapy for Sarcoma: Case Report and Literature Review
Skorupa A, Beldner M, Kraft A, Montero AJ, Cancer Biol Ther, 7/1/2007
Metastatic Chest Wall Malignant Peripheral Nerve Sheath Tumor Responding to Sorafenib: Case Report and Literature Review
Gudena V, Verma N, Post G, Kizziah M, Fenning R, Montero AJ, Cancer Biol Ther, 6/1/2007
Join now to see all

Authored Content

Everywhere Winds: Pandemic Haiku for the SpiritMarch 2022
We Don't Have All the Answers, and We Don't Have ToMay 2021

Press Mentions

ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast CancerDecember 10th, 2024
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab Will Be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024November 1st, 2024
What Is Metastatic Breast Cancer? Doctors Explain the Advanced Form of the DiseaseSeptember 14th, 2021
Join now to see all